Electromed (NSDQ:ELMD) announced that it launched the SmartVest Connect app for personalized high-frequency chest wall oscillation (HFCWO) therapy management for people with compromised pulmonary function.
The app, available on iOS and Android platforms, is designed to securely connect to the SmartVest SQL through Bluetooth technology and allow patients and healthcare teams to track therapy in real-time and collaborate on decisions for improving therapy and outcomes.
Users of the app will be able to more easily connect with their SmartVest therapy and set personal therapy reminders and real-time monitoring, according to a news release.
SmartVest SQL has been on the market since it won FDA approval in 2014. It is designed to electronically delivers high-frequency energy to the chest walls to clear the airways, promoting bronchial drainage for patients with cystic fibrosis, cerebral palsy and other diseases that cause blockages.
“Since launch in 2017, SmartVest Connect has enhanced treatment plans for patients with bronchiectasis and other chronic lung conditions that require ongoing airway clearance therapy,” Electromed president & CEO Kathleen Skarvan said in the release. “Beginning today, patients can enjoy the benefits of staying connected to their HFCWO therapy right from their mobile device.
“This new feature will enhance our customers’ experiences and allow them to take a more active role in their therapy, monitoring performance wherever life takes them next.”